DIGIPD is structured into five, closely interacting work packages:
The goal of this WP is to coordinate and manage the project. It deals with reporting, organization of project meetings, dissemination and contract issues.
Partners: Fraunhofer SCAI, University of Namur, Telecom SudParis-IPP; associated partner: Association Parkinson Madrid
Contact: Prof. Dr. Holger Fröhlich, Fraunhofer SCAI Send email
The goal of WP2 is to collect additional data (gait, face movement, voice and video recordings) and to define a hardware & software infrastructure for WP3 & 4. In addition, WP2 will deliver a web based data catalogue for all datasets available to the consortium.
Partners: Fraunhofer SCAI, Paris Brain Institute – Institut du Cerveau (ICM), University of Luxembourg, University Medical Center Erlangen, Telecom SudParis-IPP, associated partner: Portabiles HCT
Contact: Prof. Dr. Jean-Christophe Corvol, ICM Send email
The goal of WP3 is to apply AI algorithms for validating the potential of digital measures for better disease diagnosis and treatment dependent prognosis. A comparison to other data types (molecular, clinical, imaging) will be performed. WP3 will deliver digital outcome measures extracted from gait, face movement and video recordings, and it will use those measures to characterize patient subgroups identified via longitudinal clustering techniques. Finally, WP3 will assess the value of digital measures in comparison to clinical scores, molecular and imaging biomarkers to predict the progression of the disease.
Partners: Fraunhofer SCAI, Paris Brain Institute – Institut du Cerveau (ICM), University of Luxembourg, University Medical Center Erlangen, Telecom SudParis-IPP
Contact: Dr. Dijana Petrovsja Delacrétaz, Télécom SudParis –Institut Polytechnique de Paris Send email
The goals of WP4 are to map molecular markers from WP3 to disease mechanisms, and to disentangle the relationship of these mechanisms to clinical outcomes, imaging diagnostics and digital outcome measures via advanced Data Mining techniques. WP4 will thus deliver a clearer understanding of digital measures in the context of existing knowledge about Parkinson’s Disease.
Partners: Fraunhofer SCAI, Paris Brain Institute – Institut du Cerveau (ICM), University Medical Center Erlangen, University of Luxembourg
Contact: Prof. Dr. Enrico Glaab, University of Luxembourg Send email
WP5 will tackle the legal, social and ethical issues raised by the project. The first goal is to make the project compliant with the applicable data protection rules, including the General Data Protection Regulation (GDPR) and, if pertinent, national rules (article 9.4 of the GDPR) for scientific research (article 89 of the GDPR). The second goal is to analyze social and ethical implications of the use of AI and sensitive patient data, specifically digital measures. WP5 will deliver a legal and ethical roadmap for the overall project, and it will make sure that the project is compliant with GDPR. Finally, the WP will explore and broadly communicate the view of patients on the use of their data for personalized healthcare and contrast it with the legal situation and the opinion of physicians.
Partners: Paris Brain Institute – Institut du Cerveau (ICM), University Medical Center Erlangen, Telecom Sud Paris, University of Namur; associated partner: Association Parkinson Madrid
Contact: Dr. Jean-Marc Van Gyseghem, University of Namur Send email
